Advanced search×
×

Hematology/Oncology Clinics of North America

Print ISSN
0889-8588
Electronic ISSN
1558-1977
Impact factor
2.778
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/08898588
Usage rank
6416
Article count
1826
Free count
6
Free percentage
0.00328587
PDFs via platforms
Sciencedirect and Mdconsult from 1996

  1. Paroxysmal Cold Hemoglobinuria

    Hematology/Oncology Clinics of North America (1982)

    Paroxysmal Cold Hemoglobinuria is a rare cause of autoimmune hemolytic anemia predominantly seen as an acute form in young children after viral illnesses and in a chronic form in some hematological malignancies and tertiary syphilis. It is a complement medicated intravascular hemolytic ane...
  2. Melanoma adjuvant therapy.

    Hematology/Oncology Clinics of North America 28(3):471 (2014) PMID 24880942

    Adjuvant therapy targets melanoma micrometastases in patients with surgically resected disease that carry a high risk of death from melanoma recurrence. In this setting, adjuvant therapy provides the greatest opportunity for cure before progression into advanced inoperable stages. In randomized clin...
  3. Hemoglobin s polymerization and red cell membrane changes.

    Hematology/Oncology Clinics of North America 28(2):155 (2014) PMID 24589260

    Different pathways lead from the simple point mutation in hemoglobin to the membrane changes that characterize the altered interaction of the sickle red blood cell with its environment, including endothelial cells, white blood cells, and platelets. Polymerization and oxidation-induced damage to both...
  4. Customized targeted therapy in Hodgkin lymphoma: hype or hope?

    Hematology/Oncology Clinics of North America 28(1):105 (2014) PMID 24287071 PMCID PMC4023679

    Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targe...
  5. Early detection, PSA screening, and management of overdiagnosis.

    Hematology/Oncology Clinics of North America 27(6):1091 (2013) PMID 24188254

    Prostate cancer diagnosis and treatment rates have increased significantly since the introduction of prostate-specific antigen (PSA) screening. Although it was initially thought that most prostate cancers would lead to death or significant morbidity, recent randomized trials have demonstrated that m...
  6. Hematology/Oncology Clinics of North America. Disorders of the platelets. Preface.

    Hematology/Oncology Clinics of North America 27(3):xiii (2013) PMID 23714316

  7. Role of additional novel therapies in myeloproliferative neoplasms.

    Hematology/Oncology Clinics of North America 26(5):959 (2012) PMID 23009932

    The recent approval of ruxolitinib (INCB018424) for myelofibrosis and the preclinical/clinical development of several additional janus kinase (JAK)-targeted agents have ushered in an era of novel therapies for advanced myeloproliferative neoplasms (MPN), which are associated with constitutive activa...
  8. Genotype-phenotype interactions in the myeloproliferative neoplasms.

    Hematology/Oncology Clinics of North America 26(5):993 (2012) PMID 23009934

    The chronic myeloproliferative neoplasms (MPNs) are clonal disorders characterized by overproduction of mature myeloid cells. They share associations with molecular abnormalities such as the JAK2V617F mutation but are distinguished by important phenotypic differences. This review first considers the...
  9. Primary central nervous system lymphoma: overview of current treatment strategies.

    Hematology/Oncology Clinics of North America 26(4):897 (2012) PMID 22794289

    Primary central nervous system lymphoma (PCNSL) is an uncommon and aggressive variant of non-Hodgkin lymphoma that involves the brain, eyes, leptomeninges, or spinal cord. Therapeutic progress has been modest, and our understanding of the molecular mechanisms that drive this disease is limited. Clin...
  10. Does my patient with a serum monoclonal spike have multiple myeloma?

    Hematology/Oncology Clinics of North America 26(2):383 (2012) PMID 22463833 PMCID PMC3319353

    A monoclonal spike on serum protein electrophoresis is a frequent finding in the general population and pathognomonic of a plasma cell dyscrasia. In otherwise healthy individuals, it is diagnostic of two asymptomatic, premalignant conditions called monoclonal gammopathy of undetermined significance...